Of the 25 Bard chemo port devices on the market, at least 15 have been identified in lawsuits filed over failures, infections and other complications among individuals who received the implantable port catheter.
The outcome of the early bellwether test trials could impact the average Bard Power Port lawsuit settlement amounts the manufacturer may need to pay to avoid hundreds of claims being remanded for individual trials.
Judge has approved a new streamlined process for plaintiffs to file Bard Power Port lawsuits directly in the U.S. District Court for the District of Arizona, where the federal litigation is centralized.
The presiding judge has determined that six Bard PowerPort lawsuits will ultimately be chosen for the first bellwether trials.
Plaintiffs and defendants suggest an initial pool of 48 Bard PowerPort lawsuits be selected as part of an initial discovery pool, which will be prepared for a series of early trial dates in the federal Multidistrict Litigation (MDL)
The FDA warns that the recalled syringes could cause infections, blood loss, increased blood clot risks, embolism and death.
Separate from a federal court MDL established earlier this year, plaintiffs estimate there will be more than 500 Bard Power Port lawsuits filed in New Jersey state courts in coming weeks and months.
The judge has asked Bard Port catheter attorneys and defendants to file a joint plan to select bellwether test cases for early trials over claims the PowerPorts are defective, leading to fractures and device failures.
A quarter of U.S. women regularly use NSAIDs like Motrin and Advil, which may increase their risk of blood clots by a factor of 11 when combined with high risk birth control, researchers warn.
A group of nearly 40 attorneys have been proposed to serve in various leadership positions in the MDL, which will take actions that benefit all plaintiffs pursuing a Bard PowerPort lawsuit
